Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on September 1, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn235
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
81/3/509    most recent
cvn235v2
cvn235v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by González, A.
Right arrow Articles by Díez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by González, A.
Right arrow Articles by Díez, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Biochemical markers of myocardial remodelling in hypertensive heart disease

Arantxa González1, Begoña López1, Susana Ravassa1, Javier Beaumont1, Teresa Arias1, Nerea Hermida1, Amaia Zudaire1 and Javier Díez1,2,*

1 Division of Cardiovascular Sciences, Centre of Applied Medical Research, University of Navarra, Pamplona, Spain
2 Department of Cardiology and Cardiovascular Surgery, University Clinic, University of Navarra, Pamplona, Spain

* Corresponding author: Javier Díez, MD, PhD. Área de Ciencias Cardiovasculares Edificio CIMA Av. Pio XII, 55 31008 Pamplona, Spain. [E-mail: jadimar{at}unav.es; Tel: 34-948-194700; Fax: 34-948-194716]

The intricate mechanisms responsible for the structural remodelling of the myocardium that facilitates the evolution to heart failure in hypertensive patients, namely in those with left ventricular hypertrophy, requires from clinicians the utilization of a multibiomarker approach for short-term and long-term stratification as well as prognostication of patients. Biochemical markers may also help to identify patients with no clinical evidence of hypertensive heart disease, and provide information about the need for more aggressive therapy during different stages of the disease, and potentially provide valuable biochemical data for the specialist. Although there is a continuous and complex interplay between biochemical and imaging markers, perhaps their use will also have the potential to modify the medical management of patients with hypertensive heart disease and therapeutic decision-making by tailoring a targeted therapy according to the predominant mechanism of myocardial remodelling. This article will review in brief the most relevant information on a panel of circulating molecules that may accomplish the criteria required to be considered as biochemical markers of the cardiomyocyte and noncardiomyocyte structural changes that occur in the hypertensive myocardium.

Time for primary review: 39 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
J. Diez and G. Ertl
A translational approach to myocardial remodelling
Cardiovasc Res, February 15, 2009; 81(3): 409 - 411.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.